Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-loss and diabetes drugs,

Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss. Together, these blockbuster drugs made Novo the most valuable publicly listed company in Europe. At one point, its market capitalization was even bigger than the size of Denmark’s economy.

Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 sales and profit outlook, which resulted in a record stock drop, a proposed class action said.